Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Shareholders of Pfizer may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Stockport left the Places for Everyone plan in 2020 and now it looks like another borough in Oldham could follow ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

A council has narrowly voted to withdraw from a controversial housing scheme for more than 10,000 new homes after months of ...

We recently published a list of Why Are These 10 Dividend Stocks Declining? In this article, we are going to take a look at ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

NEW YORK, February 12, 2025--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...